Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy

Trinh, Hon, Pinkham, Mark Blayne, Lehman, Margot, Zarate, Dannie, Dauth, Margaret, McGrath, Margaret, McCaffrey, Elizabeth, Mai, Gang Tao and Horwood, Keith (2016) Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy. Clinical Respiratory Journal, 10 4: 428-434. doi:10.1111/crj.12233


Author Trinh, Hon
Pinkham, Mark Blayne
Lehman, Margot
Zarate, Dannie
Dauth, Margaret
McGrath, Margaret
McCaffrey, Elizabeth
Mai, Gang Tao
Horwood, Keith
Title Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy
Journal name Clinical Respiratory Journal   Check publisher's open access policy
ISSN 1752-699X
1752-6981
Publication date 2016-07
Year available 2014
Sub-type Article (original research)
DOI 10.1111/crj.12233
Open Access Status Not Open Access
Volume 10
Issue 4
Start page 428
End page 434
Total pages 7
Place of publication Hoboken, United States
Publisher Wiley-Blackwell Publishing
Collection year 2017
Language eng
Formatted abstract
Background and Aim
Thoracic radiotherapy administered concurrently with chemotherapy is the standard of care for patients with inoperable stage III non-small cell lung cancer, but the optimal chemotherapy regimen is not clearly established. The objective of this study was to assess outcomes in a large cohort of patients treated with curative-intent using carboplatin and paclitaxel.

Methods
Consecutive patients undergoing curative-intent radiotherapy to 60–66 Gy in 30–33 daily fractions with concurrent weekly carboplatin (AUC = 2) and paclitaxel (45 mg/m2/week) between March 2004 and May 2012 were identified from a prospective database and reviewed individually. A minimum follow-up of 3 months was required unless death occurred sooner. Response to treatment was defined according to established guidelines on re-staging computed tomography scan at 3 months. Toxicities were assessed using a standardised scoring system.

Results
One hundred and seven patients were analysed. The median follow-up was 43.5 months. Three months after treatment, a complete or partial response was observed in 72 patients (68%), and nine patients (8%) had already died. The overall locoregional failure rate was 47%, and failure eventually occurred at any site in 75 patients (70%). Median progression-free survival, and median survival were 15 and 22 months, respectively. Grade 3–4 neutropaenia, thrombocytopaenia, nephrotoxicity, oesophagitis and pneumonitis were observed in 15%, 1%, 3%, 11% and 9% of patients during treatment, respectively. There was one episode of fatal radiation pneumonitis.

Conclusion
Treatment with thoracic radiotherapy and concurrent carboplatin and paclitaxel chemotherapy is feasible. Survival and toxicity outcomes compare favorably to those reported using cisplatin-based regimens.
Keyword Carboplatin
Chemotherapy
Non-small cell lung cancer
Paclitaxel
Radiotherapy
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 20 Jan 2015, 00:20:28 EST by System User on behalf of Scholarly Communication and Digitisation Service